Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000905718-21-001266
Filing Date
2021-10-04
Accepted
2021-10-04 16:10:31
Documents
2
Group Members
ABINGWORTH BIOVENTURES VII, LP

Document Format Files

Seq Description Document Type Size
1 SC 13D jasper_13dsep242021.htm SC 13D 64055
2 JOINT FILING AGREEMENT jasper_13dsep242021ex1.htm EX-1 7843
  Complete submission text file 0000905718-21-001266.txt   73516
Mailing Address 38 JERMYN STREET LONDON X0 SW1Y 6DN
Business Address 38 JERMYN STREET LONDON X0 SW1Y 6DN 44 (0)20 7534 1500
Abingworth LLP (Filed by) CIK: 0001397144 (see all company filings)

EIN.: 980518585 | State of Incorp.: X0 | Fiscal Year End: 0630
Type: SC 13D

Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Subject) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91228 | Film No.: 211302815
SIC: 2836 Biological Products, (No Diagnostic Substances)